At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 13 enrolled
Drug / intervention
Danicopan +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Proof-of-Concept, Randomized, Double-Blinded, Placebo-Controlled Study of ACH-0144471 Treatment for 6 Months in Patients With C3 Glomerulopathy (C3G), With an Open-label Extension
In Brief
A Phase 2 clinical trial evaluating Danicopan and Placebo for C3 Glomerulopathy and 2 related conditions. Completed, enrolled 13 participants across 7 sites in 2 countries.
Detailed Summary
The primary purpose of this proof-of-concept clinical study was to evaluate the efficacy and safety of the study drug, ACH-0144471 (also known as danicopan and ALXN2040), in participants with C3G who also had significant proteinuria attributable to C3G.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedDec 2017
Enrollment StartJun 2018
Primary CompletionDec 2019
Study CompletionDec 2020
TodayJul 2026
First PostedDec 11, 2017
Enrollment StartJun 12, 2018
Primary CompletionDec 11, 2019
Study CompletionDec 18, 2020
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 8.6 years ago
Interventions
Danicopandrug
Danicopan was administered as an oral tablet.
Placebodrug
Matching placebo was administered as an oral tablet.